This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

5W Public Relations Adds Cold-EEZE® To Its Consumer Brands Client Roster

Stocks in this article: PRPH

NEW YORK, April 13, 2011 /PRNewswire/ -- 5W Public Relations, one of the 25 largest PR Agencies in the U.S., today announced the addition of Cold-EEZE to its diverse roster of consumer clients. Cold-EEZE is clinically proven to reduce the duration and symptoms of the common cold including cough, stuffy nose, sore throat, sneezing, post-nasal drip and hoarseness.

"5WPR is extremely excited to be named PR Agency of Record for Cold-EEZE," said Ronn Torossian, CEO of 5W Public Relations. "We have seen tremendous growth in our consumer wellness division in the last few years and look forward to creating added awareness and excitement to the Cold-EEZE brand."

Cold-EEZE is the No. 1 pharmacist-recommended zinc cold remedy and the proprietary (zinc gluconate) formula is believed by researchers to interfere with the cold virus' ability to reproduce. Cold-EEZE uses natural flavors and has no preservatives or colors. It is non-drowsy, non-agitating and does not affect blood pressure. It actually shortens your cold to help you get well sooner.

5W Public Relations will execute a comprehensive integrated public relations program to promote Cold-EEZE in the consumer marketplace. Key elements will include media relations, celebrity integrations, co-branded partnerships, special events and more.

ABOUT 5W PUBLIC RELATIONS

5W Public Relations ( www.5wpr.com) is a full-service public relations agency known for implementing cutting-edge, customized campaigns designed to drive our clients' business goals and objectives. 5WPR was founded by Ronn Torossian in 2003, and the energetic and focused culture earned the PR firm a spot on the INC. 500 list and recognition as the nation's "fastest-growing PR agency" three years in a row. Our 24/7 approach led the industry's foremost trade magazine to describe 5WPR as "aggressive in a way that clearly resonates with clients looking for a firm staffed with Type A-plus personalities, a BS-free approach, and results from Day One."

About ProPhase Labs

ProPhase Labs (NASDAQ: PRPH) is a diversified natural health medical science company. It is a leading marketer and manufacturer of the Cold-EEZE® family of lozenges and sugar free tablets clinically proven to significantly reduce the severity and duration of the common cold. Cold-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. ProPhase Labs has several wholly owned subsidiaries including a manufacturing unit, which consists of an FDA approved facility to manufacture Cold-EEZE lozenges and fulfill other contract manufacturing opportunities. ProPhase also owns 50% of Phusion Laboratories, LLC ("Phusion"). Phusion licenses a revolutionary proprietary technology that has the potential to improve the delivery and/or efficacy of many active ingredients or compounds. The joint venture plans to formulate and test products to exploit market opportunities within ProPhase's robust OTC distribution channels. For more information, visit www.ProPhaseLabs.com.

CONTACT:  Ronn Torossian, +1-212-999-5585, ronn@5wpr.com

SOURCE 5W Public Relations

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs